Turn Therapeutics to Present Initial Phase 2 Dermatitis Drug Data, Optimized Study Design
TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (2.3× avg).
Summary
Turn Therapeutics announced it will present initial findings from its Phase 2 trial of GX-03 for atopic dermatitis on a Tuesday webcast. The company will also share an optimized study design for the remaining stage of the trial. This follows the strong interim Phase 2 results for GX-03 reported on June 1st, and preclinical data published on May 27th. The stock is gaining in anticipation of this detailed presentation. The presentation of initial findings and, critically, an optimized study design for the remaining Phase 2 trial provides important updates on the development path of its lead drug candidate. The webcast presentation is scheduled for Tuesday.
At the time of this announcement, TTRX was trading at $7.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.1M. The 52-week trading range was $2.57 to $26.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.